Selecting an Optimal Staging System for Hepatocellular Carcinoma

被引:81
作者
Hsu, Chia-Yang [1 ,2 ,3 ]
Hsia, Cheng-Yuan [1 ,4 ]
Huang, Yi-Hsiang [2 ,5 ]
Su, Chien-Wei [1 ,2 ]
Lin, Han-Chieh [1 ,2 ]
Lee, Pui-Ching [2 ]
Loong, Che-Chuan [1 ,4 ]
Chiang, Jen-Huey [1 ,6 ]
Huo, Teh-Ia [2 ,7 ]
Lee, Shou-Dong [1 ,2 ]
机构
[1] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Taipei 112, Taiwan
[3] Natl Yang Ming Univ Hosp, Dept Med, Yilan, Taiwan
[4] Taipei Vet Gen Hosp, Dept Surg, Taipei 112, Taiwan
[5] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan
[6] Taipei Vet Gen Hosp, Dept Radiol, Taipei 112, Taiwan
[7] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan
关键词
Barcelona Clinic Liver Cancer; Cancer of the Liver Italian Program; Child-Turcotte-Pugh; cirrhosis; hepatocellular carcinoma; Japan Integrated Scoring; Tokyo score; tumor-node-metastasis; LIVER-DISEASE; PROGNOSTIC MODEL; CLIP; MANAGEMENT; SURVIVAL; JAPAN; SCORE; BCLC; JIS; TNM;
D O I
10.1002/cncr.25044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Selecting an appropriate staging system is crucial to predict the outcome of patients with hepatocellular carcinoma (HCC). The optimal prognostic model for HCC is under intense debate. This study investigated the prognostic ability of the 5 currently used staging systems, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Japan Integrated Scoring (JIS) system, tumor-node-metastasis (TNM), and Tokyo score, for HCC. METHODS: Between 2002 and 2008, 1713 prospectively enrolled HCC patients were compared for their long-term survival by using the Akaike information criterion (AIC) according to the staging or scoring methods of these 5 models. RESULTS: The mean and median follow-up duration was 18 and 14 months, respectively. Among all patients, the CLIP staging system had the lowest AIC value in comparison with other systems in the Cox proportional hazards model, followed by the Tokyo score, JIS score, BCLC staging system, and TNM staging system. Patients undergoing curative treatment had a significantly better survival in comparison with patients undergoing noncurative treatment (P < .001). When the predictive accuracy of the staging systems was analyzed according to treatment strategy, the CLIP staging system had the lowest AIC value and remained the best prognostic model in patients undergoing curative (801 patients) and noncurative (912 patients) treatment. CONCLUSIONS: The CLIP staging system is the best long-term prognostic model for HCC in a cohort of patient with early to advanced stage of HCC. Its predictive accuracy is independent of the treatment strategy. Selecting an optimal staging system is helpful in improving the design of future clinical trials. Cancer 2010;116:3006-14. (C) 2010 American Cancer Society
引用
收藏
页码:3006 / 3014
页数:9
相关论文
共 37 条
[1]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[2]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[3]   Survival of patients with hepatocellular carcinoma in cirrhosis:: a comparison of BCLC, CLIP and GRETCH staging systems [J].
Camma, C. ;
Di Marco, V. ;
Cabibbo, G. ;
Latteri, F. ;
Sandonato, L. ;
Parisi, P. ;
Enea, M. ;
Attanasio, M. ;
Galia, M. ;
Alessi, N. ;
Licata, A. ;
Latteri, M. A. ;
Craxi, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (01) :62-75
[4]   Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - Analysis of 2010 Taiwanese patients [J].
Chen, Chien-Hung ;
Hu, Fu-Chang ;
Huang, Guan-Tarn ;
Lee, Po-Huang ;
Tsang, Yuk-Ming ;
Cheng, Ann-Lii ;
Chen, Ding-Shinn ;
Wang, Jung-Der ;
Sheu, Jin-Chuan .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (09) :1630-1639
[5]   Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization [J].
Cho, Yun Ku ;
Chung, Jin Wook ;
Kim, Jae Kyun ;
Ahn, Yong Sik ;
Kim, Mi Young ;
Park, Yoon Ok ;
Kim, Wan Tae ;
Byun, Jong Hoon .
CANCER, 2008, 112 (02) :352-361
[6]   The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update [J].
El-Serag, H ;
Davila, JA ;
Petersen, NJ ;
McGlynn, KA .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (10) :817-823
[7]   Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study [J].
Farinati, Fabio ;
Sergio, Adriana ;
Baldan, Anna ;
Giacomin, Anna ;
Di Nolfo, Maria Anna ;
Del Poggio, Paolo ;
Benvegnu, Luisa ;
Rapaccini, Gianludovico ;
Zoli, Marco ;
Borzio, Franco ;
Giannini, Edoardo G. ;
Caturelli, Eugenio ;
Trevisani, Franco .
BMC CANCER, 2009, 9
[8]  
FEINSTEIN AR, 1972, CLIN PHARMACOL THER, V13, P609
[9]   Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998 [J].
Ferenci, P ;
Lockwood, A ;
Mullen, K ;
Tarter, R ;
Weissenborn, K ;
Blei, AT .
HEPATOLOGY, 2002, 35 (03) :716-721
[10]   Key concepts in model selection: Performance and generalizability [J].
Forster, MR .
JOURNAL OF MATHEMATICAL PSYCHOLOGY, 2000, 44 (01) :205-231